{{Drugbox
| Verifiedfields = 
| Watchedfields = 
| verifiedrevid = 
| IUPAC_name = (1S,2R,10R,11S,14S,15S)-14-[(1R)-1-hydroxyethyl]-15-methyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadec-6-en-5-one
| image = Oxogestone.svg
| width =

<!--Clinical data-->
| tradename = 
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category = 
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = 
| legal_UK = 
| legal_US = 
| legal_status = 
| routes_of_administration =

<!--Pharmacokinetic data-->
| bioavailability = 
| protein_bound = 
| metabolism = 
| elimination_half-life = 
| excretion =

<!--Identifiers-->
| CAS_number_Ref = 
| CAS_number = 3643-00-3
| CAS_supplemental = 
| ATC_prefix = 
| ATC_suffix = 
| PubChem = 19275
| DrugBank_Ref = 
| DrugBank = 
| ChemSpiderID_Ref = 
| ChemSpiderID = 18186
| UNII = A98264FU0C

<!--Chemical data-->
| C=20 | H=30 | O=2
| molecular_weight = 302.451 g/mol
| smiles = CC(C1CCC2C1(CCC3C2CCC4=CC(=O)CCC34)C)O
| StdInChI_Ref = 
| StdInChI = 1S/C20H30O2/c1-12(21)18-7-8-19-17-5-3-13-11-14(22)4-6-15(13)16(17)9-10-20(18,19)2/h11-12,15-19,21H,3-10H2,1-2H3/t12-,15+,16-,17-,18-,19+,20-/m1/s1
| StdInChIKey_Ref = 
| StdInChIKey = CNOGNHFPIBORED-JIKCGYBYSA-N
| synonyms = (20''R'')-20-Hydroxy-19-norpregn-4-en-3-one
}}

'''Oxogestone''' ([[International Nonproprietary Name|INN]]) is a [[steroid]]al [[progestin]] related to the [[19-norprogesterone]] derivatives that was synthesized in 1953 and was developed as an [[injection (medicine)|injectable]] [[hormonal contraceptive]] in the early 1970s but was never marketed.<ref name="Elks2014">{{cite book|author=J. Elks|title=The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies|url=https://books.google.com/books?id=0vXTBwAAQBAJ&pg=PA919|date=14 November 2014|publisher=Springer|isbn=978-1-4757-2085-3|pages=919–}}</ref><ref name="pmid4679651">{{cite journal | vauthors = Farkas M, Szontágh FE | title = Clinical experiences concerning the intramuscular contraceptive oxogestone | journal = Acta Eur. Fertil. | volume = 3 | issue = 1 | pages = 37–43 | year = 1972 | pmid = 4679651 | doi = | url = http://www.popline.org/node/489650}}</ref><ref name="pmid5032612">{{cite journal | vauthors = Ruíz Velasco V, Alisedo Aparicio LE | title = [Side effects of depot contraceptives] | language = Spanish; Castilian | journal = Prensa Med Mex | volume = 37 | issue = 1 | pages = 25–9 | year = 1972 | pmid = 5032612 | doi = | url = http://www.popline.org/node/489759}}</ref><ref name="BassolGarza-Flores1994">{{cite journal|last1=Bassol|first1=Susana|last2=Garza-Flores|first2=Josue|title=Review of ovulation return upon discontinuation of once-a-month injectable contraceptives|journal=Contraception|volume=49|issue=5|year=1994|pages=441–453|issn=0010-7824|doi=10.1016/0010-7824(94)90003-5|pmid=8045131}}</ref> A 3-[[phenylpropanoic acid|phenylpropionate]] derivative, [[oxogestone phenpropionate]], also exists.<ref name="Elks2014" />

==References==
{{Reflist|2}}


{{Progesterone receptor modulators}}

[[Category:Hormonal contraception]]
[[Category:Norpregnanes]]
[[Category:Progestogens]]


{{genito-urinary-drug-stub}}
{{steroid-stub}}